Lanvin Group Holdings Limited announced on November 13, 2026 that it received a notice from the New York Stock Exchange on November 10, 2026 indicating the company is not in compliance with the NYSE's minimum average closing price requirement of US$1.00 per share.

Key Highlights

  • Deficiency notice received: The NYSE notified Lanvin Group on November 10, 2026 that its ordinary shares failed to maintain a minimum average closing price of US$1.00 per share over a consecutive 30 trading-day period.
  • Six-month cure period: Pursuant to NYSE rules, the company has six months following receipt of the deficiency letter to regain compliance with the minimum share price requirement.
  • Compliance intent filed: The company notified the NYSE within ten business days of receipt of its intent to cure the deficiency.
  • Reverse stock split considered: The company disclosed it intends to consider available alternatives, including but not limited to a reverse stock split subject to shareholder approval, if necessary to cure the non-compliance.
  • Shares remain listed: The NYSE notice has no immediate effect on the continued listing of ordinary shares, which will continue to trade on NYSE:LANV during the cure period, subject to compliance with other listing requirements.
  • No business impact anticipated: According to the filing, the notice "is not anticipated to impact the Company's ongoing business operations."

Lanvin Group Discloses NYSE Listing Standard Non-Compliance and Cure Options

Lanvin Group Holdings Limited, listed on NYSE:LANV, disclosed in a press release dated November 13, 2026 that it received a deficiency notice from the New York Stock Exchange on November 10, 2026. According to the filing, the company is not in compliance with the NYSE's continued listing standard that requires a minimum average closing price of US$1.00 per share over a consecutive 30 trading-day period for its ordinary shares.

The filing states that, under NYSE rules, the company has a six-month period following receipt of the deficiency letter to regain compliance. The company can satisfy the requirement at any time during the cure period if, on the last trading day of any calendar month within that period, the ordinary shares have a closing price of at least US$1.00 per share and an average closing price of at least US$1.00 per share over the 30 trading-day period ending on that last trading day. The company disclosed it has already notified the NYSE of its intent to cure the deficiency within the required ten business day window.

Regarding potential remedies, the company stated it "intends to consider available alternatives, including but not limited to a reverse stock split that is subject to shareholder approval, if necessary to cure the stock price non-compliance." The filing notes the deficiency notice carries no immediate effect on the listing status of the ordinary shares, which will continue to trade under the symbol "LANV" on the NYSE during the cure period, provided the company continues to meet the exchange's other continued listing requirements. The filing also contains forward-looking statements, which the company identifies as subject to its cautionary language and applicable risks.

What Was Disclosed

Lanvin Group disclosed receipt of an NYSE minimum share price deficiency notice dated November 10, 2026, a six-month cure period under NYSE rules, the company's stated intent to cure, and potential remedies including a shareholder-approved reverse stock split.